NCT03792867View on ClinicalTrials.gov

Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

March 31, 2024

Conditions
Retroperitoneal Sarcoma
Interventions
DRUG

Doxorubicin

Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.

Trial Locations (1)

169610

National Cancer Centre Singapore, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER

NCT03792867 - Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma | Biotech Hunter | Biotech Hunter